Proven protocol for reversing the biomarkers of aging. Patent pending, clinal study completed product for sale.
EXECUTIVE SUMMARY
Company: Extended Longevity, Inc., is engaged in the development, manufacture, formulation, and production of branded phytotherapeutic products for sale in the $216 billion-dollar anti-aging industry. The Company is currently implementing its product strategy with a planned national rollout of its Extended Longevity Protocol Phytotherapeutic Extract product lines.
Products
The products are formulated using our proprietary process: Phytotherapeutic Extract and Formulation, which preserves and enhances the most beneficial therapeutic values of medicinal plants and delivers them in a safe and efficacious form. The Company uses a process using proprietary protocols and equipment. The extract contains the hydrophobic components of the plant and is a powerful therapeutic agent. Our products include: Pinetonal™, Thyvolve™, Bluecosig™, CMEnhance™, Inflasolve™, Stemegenis™, Sentophagy™, Telogenic™, Epiverse™, Cognilace™, Elastage ECM™, Cnidium M™, Cognilace™ and Emophix™.
Summary: Human Aging is a process of time-sequenced systemic degeneration followed by disintegration and death. We are facing a significant health problem as the “Baby Boomer” generation (ages 57-75) age. Diseases of aging such as heart disease, diabetes, cancer, Alzheimer’s disease, and other disorders will increasingly cause sickness and suffering for this population. There is currently no ‘treatment’ to prevent or reverse aging. Can this be stopped and even reversed?
Extended Longevity's advanced anti-aging protocol can ameliorate the diseases of aging, extend longevity and improve healthspan. Based upon breakthrough bioinformatic research in anti-aging, coupled with the development of effective phytotherapeutic extract interventions, the Extended Longevity protocol addresses ten determinant factors of aging that lead to failures in biological, DNA, cellular, and systemic health. Our mission is to slow and reverse aging, reduce the diseases of aging, extend life, and optimize health. Our deliverables are a natural
products, facilitated by age detection through testing of aging biomarkers.
Project impact: Reducing disease and related interventions (i.e. heart surgery, dialysis, etc.) will relieve suffering, reduce health care expense and provide a better quality of life for billions.
Project Description: Aging is characterized by the accumulation of deleterious changes in cells and tissues that increase the risk of disease and can result in an increase in mortality. These changes are the primary risk factors for many aging related diseases, including cancer, diabetes, cardiovascular disorders, and neurodegenerative diseases. As the world’s population ages and the burden of chronic age-related diseases rises, there is a need to develop novel therapeutic approaches to alleviate the biological burden of aging. Extended Longevity specializes in phytotherapeutic extracts rooted in Complementary and Alternative Medicine (CAM) to address the diseases of aging, support health, and extend the human lifespan.
These formulations are designed to enhance healthspan by addressing ten determinant factors of aging:
1. Pineal, Hypothalamus, Super Chiasmatic nucleus dysregulation;
2. Telomere attrition;
3. Epigenetic alterations;
4. Thymic Involution;
5. Blood Signaling of cellular aging;
6. Mitochondrial dysfunction;
7. Cellular senescence;
8. Stem Cell Exhaustion;
9. Inflammaging; and
10. Extracellular Matrix stiffening and crosslinking.
The phytomedicinal ingredients in the Extended Longevity formulations have been used in humans for over 5000 years and are considered Generally Recognized as Safe (GRAS) by the FDA.
To date, a small cohort of adults (ages 42-74 years old) have used the Extended Longevity protocol every day for at least two years. These individuals show remarkable age deceleration changes in aging biomarkers, including cytosine methylation on the epigenome, telomere length, and inflammation as measured by high sensitivity C-reactive protein (CRP) test, indicating a significant decrease in biological age. Based on these results, we recently initiated an exploratory trial to evaluate the effect of Extended Longevity Protocol in older adults (age 55-75).
This grant will enhance the value of our novel longevity protocol and accelerate wide scale adoption by the aging baby boomer population and the younger first-adopters who wish to preserve and extend their longevity and healthspan.
Aging, the primary risk factor for cancer, diabetes, cardiovascular disorders, and neurodegenerative diseases, has hitherto not been prevented, slowed, or reversed. In recent years, our understanding of the cellular and molecular basis of aging has been transformed. Extended Longevity is harnessing this knowledge along with its extensive knowledge of Complementary and Alternative Medicine (CAM) to address the diseases of aging, support health, and extend the human lifespan.
Statement of Significance: Until now, there have been no proven treatments reversing the conditions of aging. While medicine continues to treat disease on an ailment-by-ailment basis, the effect of aging on the healthspan of the aging population has not received the consideration it warrants. For example, cancer is treated by a combination of surgery, chemotherapy, and radiation, and not by addressing the underlying causes that may be aging dependent. Yet, according to the National Cancer Institute (NCI), cancer is one of the leading causes of mortality, especially affecting the elderly.
The world population is aging. In the US, the aging population is being accelerated by the Baby Boom generation (born between 1946-1964) turning 65 years old. Between 2015 and 2030, the number of people in the world aged 60 years or over is expected to grow by 56%, from just over 900 million to nearly 1.5 billion. By 2050, this “silver tsunami” is expected to jump to two billion and will account for 25% of the world population. We believe that addressing the aging process is the most significant opportunity to effect a broad population and provide a path to health and wellbeing.
Outcomes:
Extended Longevity’s mission pursues an exciting and revolutionary approach to research and product development: targeting the pathology and underlying biology of aging itself. Therapies derived from this kind of effort have the potential to treat multiple diseases simultaneously.
Research has determined that aging is largely controlled by 10 primary internal biological factors, now understood to be reversible. By identifying the determinant factors of aging and designing synergistic and mimetic phytotherapeutic analogs to the underlying structure of molecules known to reverse the conditions of aging, Extended Longevity seeks to decelerate the biomarkers of aging and consequently reduce the incidence of the diseases of aging. Thus, extending both the lifespan and healthspan for a broad demographic of the population of the US and the world.
Capacity for Success:
To address aging, Extended Longevity is advancing the development of a longevity protocol that consists of 10 proprietary formulations designed to target the determinant factors of aging. Our work is grounded in extensive evaluation of the scientific literature and our knowledge of traditional eastern and western medicine.
While many biotechnology companies are searching for novel compounds and new drugs to solve the problem of aging, we went back to the roots of medicine and researched plant-based solutions that have years of research and proven efficacy to find what, if any, natural compounds that achieve the same foundational results. Extended Longevity's formulations, rooted in traditional systems of medicine that have been widely used throughout the world for thousands of years to support and maintain health. Over the past few decades, the medicinal properties of over 13,000 plants have been researched. To date, over 300 anti-aging compound activities have been reported in the scientific literature. Of these, 185 compounds are derived from natural products and 55 are natural product extracts.
The Extended Longevity formulations target multiple hallmarks of aging. Instead of looking at aging as a single event, it is recognized that a synergy of ten different biological events is at play. By isolating each of the processes we can focus on reversing them, and then address all of the determinant factors of aging together, as a whole integrated organism.
Management
Steven M. Schorr, Age 70, Founder, CEO, CSO and Director, of Extended Longevity, Inc.
Mr. Schorr is an executive with 47+ years of experience in the development of biotechnology, products, and businesses. He is a patented inventor/entrepreneur and scientist. His duties have included product conception, design, and development, manufacturing, maintaining research laboratories and directing scientific research programs; directing international business planning and marketing strategies; and includes overseeing all production, scientific, legal and international affairs. He has authored 20 U.S. and International Patents.
Hamiel O. Schorr, age 43, COO and Director, of Extended Longevity, Inc.
A graduate of the Arizona State University Industrial and Product Design program at the School of Architecture and Environmental Design, Mr. Schorr has led product identity and branding development teams. He is an expert in the use of glass distillation and extraction equipment. Responsible for product development, natural product formulation and production, product concept ideation and creation, graphic design, and sales and marketing. He led the production team in the manufacture of coffee fruit extract for KonaRed, Inc.
Important Facts
§ The Company has completed development of its phytomedicinal technology: “Phytotherapeutic Extraction” targeted to produce products sold in the Longevity and Anti-aging Medicinal Market and online retail distribution channels.
§ Extraction facilities have been established at its Maui, Hawaii facilities with capabilities to meet current production demand for its products. To date, production is capable of producing over 50,000 units per month.
§ The Company has developed a portfolio of intellectual property including Patents Pending; Trademarks and Copyrights with the United States Patent & Trademark Office (USPTO).
§ Test marketing for the products have been successfully conducted in Hawaii and over the Internet, resulting in steady reorders from consumers.
§ The Company has launched its website and online store (www.extendedlongevity.com)
§ In a soft test launch in 2020-2022, the Company has realized over $100,000 in sales for its Extended longevity products, including the sale of its fourteen (14) Phytotherapeutic extracts.
§ Epigenetic Clock Test results for a small cohort have been successful in demonstrating a 15-year age deceleration in a 67-year-old and 74-year old (men).
§ Telomere tests have demonstrated the increased telomere growth equivalent to a 10–20-year-old, in men 41, 67 and 74 years old. Results have shown 9,000+ base pair telomere